Quick rundown on menopause Things that we ignore

-
 1. What it is Menopause is diagnosed after 12 consecutive months without a period. The average age in most countries is around 45–55, but it varies.  2. Key phases   Perimenopause: The transition period before menopause, often 4–8 years. Hormones fluctuate, cycles become irregular.   Menopause: The point when ovaries stop releasing eggs and estrogen/progesterone drop.   Postmenopause: The years after menopause. Symptoms often ease, but health risks like osteoporosis and heart disease increase. 3. Common symptoms   Hot flashes + night sweats Irregular periods → then no periods Sleep problems Mood changes, anxiety, or depression   Vaginal dryness, lower libido Bone density loss, joint pain 4. Why it matters for workforce diversity In companies like Amber Distributors, menopause affects women typically in their late 40s to 50s. If your workforce is predominantly male and older, you might miss how menopause impacts productivity, a...
Post a Comment

CAPE TOWN, Feb 15 (Reuters) - South Africa's drugs regulator SAHPRA said on Monday it has approved an implementation study of Johnson & Johnson's COVID-19 vaccine, clearing the way to start the country's first inoculations among health workers.

-

 * Govt still reviewing J&J’s full market application

* Implementation study is to vaccinate health workers
* S.Africa expected to receive J&J’s vaccines this week (Adds detail, quotes)

By Wendell Roelf

South Africa is yet to start its COVID-19 vaccination programme and the government has decided to go with the J&J dose after trial results this month showed AstraZeneca’s two-shot vaccine was less effective against the new variant of the coronavirus dominating South African infections.

“SAHPRA has approved the implementation study,” the regulator said in response to Reuters questions, but added it was still reviewing its separate full market application.

The implementation study, similar to the final phase of a vaccine trial, will test the effects of the vaccine in the field after it is administered to around 350,000 to 500,000 health care workers.

The first batch of J&J’s 80,000 doses are expected to arrive this week, President Cyril Ramaphosa told lawmakers on Thursday.

J&J was the first pharmaceutical major to apply to the local regulator in December to register its COVID-19 vaccine, although Pfizer and AstraZeneca have also applied.

South Africa is currently the hardest hit African country and accounts for over a third of the continent’s infections and almost half of the deaths, led primarily by the new, more contagious variant called 501Y.V2.

The South African Health Products Regulatory Authority (SAHPRA) said J&J has not yet submitted a special domestic application for emergency use authorisation of its vaccine – known as a Section 21 application.

Normally valid for six months, Section 21 authorisation allows emergency use of a product that is unregistered, SAHPRA officials said.

However, J&J’s application for full market registration was being processed as part of a rolling review approach, which allows data to be evaluated by SAHPRA as it becomes available, the regulator said. “The rolling review has received its second batch of data and is under review. The full process is estimated to be complete after four batches of rolling data (are received),” said SAHPRA.

This is one of several methods the domestic regulator is pursuing to help fast-track vaccine approvals. (Reporting by Wendell Roelf; editing by Promit Mukherjee and Jason Neely)

Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email letters@dailymaverick.co.za

 

Comments

Post a Comment

Popular posts from this blog

MultiChoice’s BEE scheme trying to find 22 000 shareholders who are missing out on millions

-
Image
  USINESS REPORT COMPANIES MultiChoice’s black economic empowerment scheme is looking for about 22 000 shareholders who owned shares and did not receive dividends of R207 million between 2006 and 2020. Picture: Karen Sandison/African News Agency(ANA) MultiChoice’s BEE scheme trying to find 22 000 shareholders who are missing out on millions By Edward West   Feb 16, 2021 CAPE TOWN - PHUTUMA Nathi, the MultiChoice black economic empowerment scheme of more than 80 000 shareholders, is looking for about 22 000 shareholders who owned shares and did not receive dividends of R207 million between 2006 and 2020. “This money belongs to our shareholders. We’re calling on them to contact us to get their money. In these tough economic times we want to do everything in our power to give them what is rightfully theirs,” Phuthuma Nathi chairperson Mandla Langa said in a statement yesterday. Phuthuma Nathi has been paying dividends every year since the start of the scheme in 2006. Am...
Read more

Fighting Drug addiction

-
 Here's the story: We sat down with a man who had a harrowing journey with addiction. He began by telling us about his early days in tertiary education, where he would occasionally smoke dagga with friends. However, his focus remained on his studies, and he worked hard to graduate and secure a qualification. After landing a job, he started building a life for himself. He got married, bought a property, and even splurged on a car. Life was good, and he felt like he was on top of the world. But one fateful night, while out with friends, he was introduced to heavier narcotics. At first, the experience was exhilarating. He described it as an elevation from the mild high of dagga to a level 5 high, where he felt invincible and euphoric. The effects would last for days, allowing him to party from Friday to Sunday without sleep. The problem, however, began to manifest on Mondays and Tuesdays every week, when the withdrawal symptoms would kick in, and he'd struggle to function at work....
Read more

This New Ultralight Aircraft May Be World’s Fastest Single-Engine Business Jet

-
Image
  The speedy LAR-01's automotive interior adds comfort and luxury. Plus: The wings detach, so the jet can be stored in a home garage. By  MICHAEL VERDON           Courtesy Flaris The  Flaris  LAR-01 has a number of striking stats, including being a ton lighter (literally) than its competitors, along with an unusually short-field landing capability, and detachable wings. But its most impressive number is the 250-knot true air speed, which its designers say makes it the world’s fastest business jet among single-engine very light jets and turboprop aircraft. Flaris says recent tests “confirmed the assumptions made previously” about the effectiveness of multiple systems, including its Garmin G600 avionics and Flaris Flight Assistance System flight computer, as well as the landing gear and emergency parachute system. But it also claims more impressive stats like the 250-knot TSA at 10,000 feet. Its 6,000-feet-per-minute climb rate, adds the compan...
Read more